Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2021-12-15 00:00:00 ET · period of report 2021-12-13 · accession 0001562180-21-007710 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-15 | 2021-12-13 | SNDX | Metzger Michael A | Pres, COO, Dir | S - Sale+OE | $19.05 | -36.6K | 17.7K | -67% | -$697.4K |
| DM | 2021-12-15 | 2021-12-13 | SNDX | Metzger Michael A | Pres, COO, Dir | M - OptEx | $6.43 | +36.6K | 19.7K | New | +$235.2K |
| DM | 2021-12-15 | 2021-12-13 | SNDX | Metzger Michael A | Pres, COO, Dir | M - OptEx | $0.00 | -36.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-13 | S | D | 34,564 | $19.05 | 17,659 | D | — | — | (F2) The sale prices ranged from $19.00 to $19.49. |
| 2 | Common | Common Stock | 2021-12-13 | M | A | 34,564 | $6.38 | 52,223 | D | — | — | |
| 3 | Common | Common Stock | 2021-12-13 | M | A | 2,045 | $7.20 | 19,704 | D | — | — | |
| 4 | Common | Common Stock | 2021-12-13 | S | D | 2,045 | $19.05 | 17,659 | D | — | — | (F2) The sale prices ranged from $19.00 to $19.49. |
| 5 | Derivative | Stock Options (Right to buy) | 2021-12-13 | M | D | 2,045 | $0.00 | 0 | D | $7.20 · — to 2025-06-01 | 2,045 Common Stock | (F3) This option is fully vested. |
| 6 | Derivative | Stock Options (Right to buy) | 2021-12-13 | M | D | 34,564 | $0.00 | 0 | D | $6.38 · — to 2029-02-06 | 34,564 Common Stock | (F3) This option is fully vested. |